<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24906" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Medullary Thyroid Cancer</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Master</surname>
            <given-names>Samip R.</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mathias</surname>
            <given-names>Priyanka M.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Burns</surname>
            <given-names>Bracken</given-names>
          </name>
          <aff>East Tennessee State University (ETSU)</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Samip Master declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Priyanka Mathias declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bracken Burns declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>15</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24906.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Medullary thyroid cancer (MTC) is a tumor arising from the parafollicular cells, or C cells, of the thyroid gland. Medullary thyroid cancer produces calcitonin, and elevated calcitonin level is an essential feature of this tumor. Recent advances in molecular pathogenesis and genetic testing have led to risk stratification of the patients and the identification of molecular targets for therapy. This activity reviews the evaluation and management of MTC and highlights the role of the interprofessional team in evaluating and improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of medullary thyroid cancer.</p></list-item><list-item><p>Review the evaluation of a patient with medullary thyroid cancer.</p></list-item><list-item><p>Summarize the treatment options for medullary thyroid cancer.</p></list-item><list-item><p>Outline the importance of care coordination among interprofessional team members to improve outcomes for patients affected by medullary thyroid cancer.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24906&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24906">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24906.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Medullary thyroid cancer is a tumor arising from the parafollicular cells, or&#x000a0;C cells, of the thyroid gland. Medullary thyroid cancer&#x000a0;produces calcitonin, and&#x000a0;elevated calcitonin level is an essential feature of this tumor. It is derived from the medullary C cells that are of neural crest origin. Recent advances in molecular pathogenesis and genetic testing have led to risk stratification of the patients and the identification of&#x000a0;molecular targets for therapy.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30838820">[1]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30829709">[2]</ext-link>&#x000a0;Prophylactic thyroidectomy is recommended for patients with mutations that put them at high risk. Various tyrosine kinase inhibitors are approved for use in&#x000a0;progressive, metastatic medullary thyroid cancer.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30800639">[3]</ext-link></p>
      </sec>
      <sec id="article-24906.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Seventy-five percent to eighty percent of medullary thyroid cancers are sporadic, and&#x000a0;the remainder&#x000a0;is familial as part of multiple endocrine neoplasias (MEN)&#x000a0;2A,&#x000a0;MEN&#x000a0;2B, and&#x000a0;familial medullary thyroid cancer (FMTC). <italic toggle="yes">RET</italic> mutations in neural crest tissue in the thyroid gland can lead to medullary thyroid cancer&#x000a0;development. Germline mutations are associated with MEN2 and FMTC medullary thyroid cancers. Forty to fifty percent of sporadic medullary thyroid cancers have acquired <italic toggle="yes">RET</italic> mutations.</p>
      </sec>
      <sec id="article-24906.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Medullary carcinoma of the thyroid constitutes approximately 4% to 10% of all thyroid cancers in the United States. Sporadic medullary thyroid cancer&#x000a0;has a peak incidence in the fifth or sixth decade of life; whereas, those medullary thyroid cancers associated with&#x000a0;MEN&#x000a0;2A or&#x000a0;MEN&#x000a0;2B peak around the second or third decade of life.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="29402183">[4]</ext-link></p>
      </sec>
      <sec id="article-24906.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>As opposed to the sporadic medullary thyroid cancer&#x000a0;which is usually unilateral, the medullary thyroid cancer&#x000a0;associated with multiple&#x000a0;MEN&#x000a0;syndromes is usually multicentric and bilateral. Often these tumors involve the upper portions of both lobes because the C cells reside predominantly in the upper poles of the thyroid gland. Paraneoplastic syndromes like Cushing syndrome and&#x000a0;carcinoid syndrome can occur as medullary thyroid cancer, and can also produce hormones such as corticotropin, serotonin, prostaglandins, and melanin.</p>
      </sec>
      <sec id="article-24906.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Medullary thyroid cancer is characterized by nests of round or ovoid cells with fibrovascular stroma. There is no follicle development as the tumor is developed from the parafollicular C cell of the thyroid.</p>
      </sec>
      <sec id="article-24906.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Approximately 75% to 95% of patients with medullary thyroid cancer&#x000a0;present as a thyroid nodule in the upper portion of the gland where C cells are primarily located. About 70% will have cervical lymphadenopathy, and a few patients have compression symptoms like dysphagia, hoarseness, or respiratory difficulty. Metastatic spread can be present in less than 10% of patients at presentation. Liver, bone, lung, and brain are common sites for metastases in medullary thyroid cancer. High calcitonin levels can cause diarrhea in a minority of patients.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="29337472">[5]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30562193">[6]</ext-link></p>
        <p>The index case in&#x000a0;FMTC and&#x000a0;MEN&#x000a0;syndrome presents similarly&#x000a0;to sporadic medullary thyroid cancer, except that presentation is often at an earlier age compared to sporadic medullary thyroid cancer.</p>
      </sec>
      <sec id="article-24906.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Fine needle aspiration (FNA) of the solitary thyroid nodule or dominant nodule for multinodular thyroid is potentially helpful in establishing the diagnosis. If the FNA is nondiagnostic, the diagnosis can be made after thyroid lobectomy on permanent histology. As the tumor cells originate from the parafollicular C cells, the pathology shows spindle-shaped cells without follicle development. Measuring serum calcitonin before FNA diagnosis is complicated by a high false-positive rate. Once the diagnosis of medullary thyroid cancer&#x000a0;is made based on histology, serum calcitonin, and carcinoembryonic antigen (CEA) should be measured. These tests help with the discovery of the hypersecreting tumor, and pre-operative levels can be compared to postoperative levels to confirm the biochemical response and can be used to measure treatment efficacy after total thyroidectomy.&#x000a0;The postoperative calcitonin and CEA doubling time provide a sensitive marker for disease progression.</p>
        <p>Ultrasonography, or other imaging of the neck such as computed tomography, is indicated once the histological diagnosis is made to evaluate for cervical lymph node involvement. The evaluation for systemic disease using CT neck and imaging of the liver by CT or MRI can be done in patients suspected of having metastatic disease. This can include patients with nodal disease and calcitonin levels greater than 400 pg/ml.&#x000a0;The sensitivity of PET and the nuclear scan is variable and is not recommended for primary evaluation for metastatic disease.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30717909">[7]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30734711">[8]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30694510">[9]</ext-link></p>
        <p>It is recommended to discuss the risks and benefits of genetic testing&#x000a0;with the patient. Genetic testing for <italic toggle="yes">RET</italic> protooncogene sequencing of exons 10, 11, and 13 through 16 is necessary for all patients with parafollicular C cell hyperplasia or sporadic medullary thyroid cancer.</p>
        <p>Since the results of genetic testing are rarely available before surgery in sporadic cases, it is recommended to do a biochemical evaluation of possible co-existing tumors associated with MEN2 syndromes&#x000a0;before surgery. Screening for hyperparathyroidism and pheochromocytoma by using serum calcium and plasma metanephrines respectively is recommended for a patient with unknown <italic toggle="yes">RET</italic> mutational status and confirmed germline <italic toggle="yes">RET</italic> status.</p>
        <p>
<bold>The American Joint Committee on Cancer (AJCC) Staging</bold>
</p>
        <p>The American joint committee on cancer (AJCC) used different tumor-node-metastasis (TNM) classification for differentiated and anaplastic thyroid cancer.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="28094848">[10]</ext-link>&#x000a0;Five-year survival for stage I, II, and III medullary thyroid cancer is 93% compared to 28% for stage IV.</p>
      </sec>
      <sec id="article-24906.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Surgical resection is the primary treatment for medullary thyroid carcinoma. Medullary thyroid carcinoma does not respond to radioactive iodine (RAI) or conventional chemotherapy. Thyroid-stimulating hormone (TSH)&#x000a0;suppression is not required for medullary thyroid cancer&#x000a0;as C cells do not have the&#x000a0;thyroid-stimulating hormone receptor. As mentioned previously, all patients should be evaluated for hyperparathyroidism and pheochromocytoma. If a pheochromocytoma is found, it should be removed prior to thyroidectomy.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30675485">[11]</ext-link></p>
        <p>
<bold>Total Thyroidectomy</bold>
</p>
        <p>&#x000a0;Total thyroidectomy is indicated for all patients with medullary thyroid cancer. Bilateral neck dissection (level IV LN) is indicated for tumors more than one centimeter in the greatest dimension, as well as for bilateral disease. It should also&#x000a0;be considered for unilateral tumors and tumors less than one centimeter, though definitive data are lacking. Total thyroidectomy greatly increases the efficacy and utility of postoperative calcitonin level monitoring as a marker for recurrence.</p>
        <p>In cases of inherited disease, it is recommended to perform total prophylactic thyroidectomy by age five or when the mutation is found, especially with <italic toggle="yes">RET</italic> mutation codon 609, 611, 618, 630, 634. In&#x000a0;multiple endocrine neoplasia&#x000a0;2B with <italic toggle="yes">RET</italic> codon 883, 918, or compound heterozygotes,&#x000a0;prophylactic total thyroidectomy&#x000a0;is recommended by age one. In patients with a less high-risk mutation in codon 768, 790, 791, 804, and 891 prophylactic surgery can be deferred if there is no family history for aggressive medullary thyroid cancer, the family agrees to postpone surgery, and annual basal calcitonin and ultrasounds are performed. Adjuvant radiotherapy has not been adequately studied but can be considered in extrathyroid extension and extensive nodal disease.</p>
        <p>
<bold>Monitoring for Recurrence</bold>
</p>
        <p>Two to three months after surgery, serum CEA and calcitonin levels should be assessed. If CEA is within normal limits and calcitonin is not detectable, then&#x000a0;the patient&#x000a0;is considered cured and has the best prognosis.&#x000a0;This group needs to be monitored by annual CEA, calcitonin, and potentially with annual ultrasound (based on symptoms and physical exam). For&#x000a0;multiple endocrine neoplasia&#x000a0;2A and 2B, annual exams for hyperparathyroidism and pheochromocytoma are prudent.</p>
        <p>Detectable calcitonin or elevated CEA two to three months after surgery raises suspicion for residual disease.&#x000a0;These patients should have a&#x000a0;neck ultrasound and in cases of calcitonin greater than 150 pg/ml, further imaging in the form of CT neck, chest, and abdomen liver protocol evaluating&#x000a0;for potential metastatic disease. If the imaging is negative&#x000a0;and the patient is asymptomatic, continue close surveillance with the physical exam and calcitonin/CEA measurements. If levels remain stable, no further imaging is needed. There is no indication to treat asymptomatic elevated calcitonin. If the imaging is positive&#x000a0;and the patient is symptomatic, surgical resection of residual lesions is indicated. In the case of unresectable disease, radiotherapy can provide potential palliative therapy.</p>
        <p>
<bold>Tyrosine Kinase Inhibitors</bold>
</p>
        <p>In cases of unresectable and symptomatic disease, tyrosine-kinase inhibitors (TKI) like vandetanib and cabozantinib may be indicated. Vandetanib is an oral receptor kinase inhibitor that inhibits <italic toggle="yes">RET</italic>, <italic toggle="yes">EGFR</italic>, and <italic toggle="yes">VEGFR</italic>. In a phase III study, which included 331 patients with advanced, unresectable, or metastatic medullary thyroid cancer, patients showed improved progression-free survival (PFS) compared to placebo.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30675485">[11]</ext-link> Cabozantinib is also an oral multikinase inhibitor that inhibits <italic toggle="yes">MET</italic>, <italic toggle="yes">RET</italic>, and <italic toggle="yes">VEGFR2.</italic>&#x000a0;A phase III EXAM study showed improvement in PFS in advanced or metastatic medullary thyroid cancer.</p>
      </sec>
      <sec id="article-24906.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Patients suffering from medullary thyroid cancer has clinical presentation similar to other thyroid diseases, hence the following differential must be kept in mind while evaluating these patients.</p>
        <list list-type="bullet">
          <list-item>
            <p>Anaplastic thyroid carcinoma</p>
          </list-item>
          <list-item>
            <p>De Quervain thyroiditis</p>
          </list-item>
          <list-item>
            <p>Follicular thyroid carcinoma</p>
          </list-item>
          <list-item>
            <p>Graves disease</p>
          </list-item>
          <list-item>
            <p>Intestinal carcinoid tumor</p>
          </list-item>
          <list-item>
            <p>Multiple endocrine neoplasia (MEN) Type 2</p>
          </list-item>
          <list-item>
            <p>Papillary thyroid carcinoma</p>
          </list-item>
          <list-item>
            <p>Thyroid lymphoma</p>
          </list-item>
          <list-item>
            <p>Thyroid nodule</p>
          </list-item>
          <list-item>
            <p>Thyrotoxicosis</p>
          </list-item>
          <list-item>
            <p>Toxic nodular goiter</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24906.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prognosis depends on the age of the patient, histologic grade, and status of surgical resection. Older patients, higher-grade lesions, and those who have incomplete surgical resection have a worse prognosis. The five-year survival for stages 1 to 3 is 93% compared to 28% for stage 4. Despite advances in genetic screening for the RET proto-oncogene, preliminary population studies have yet to show a definitive impact on disease prognosis.<xref ref-type="bibr" rid="article-24906.r18">[12]</xref>&#x000a0;A study concluded that disease-free survival in younger patients with hereditary MTC was best predicted by TNM staging and pre-operative basal calcitonin level of less than 30 pg/ml.<xref ref-type="bibr" rid="article-24906.r19">[13]</xref></p>
      </sec>
      <sec id="article-24906.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Permanent hypothyroidism and recurrent laryngeal nerve palsy reportedly occur in less than 2% of virgin neck dissection. Reoperation is associated with a higher risk of these injuries.</p>
      </sec>
      <sec id="article-24906.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education is mandatory as after total thyroidectomy patients need lifelong thyroxine. Patients are also advised to get physical examination twice yearly for the first two years and then yearly thereafter. Serum calcitonin and CEA level should be monitored twice yearly for two years and then yearly thereafter to identify the recurrence or distant metastasis. Neck ultrasound and other investigations like CT should be advised if calcitonin is high.</p>
      </sec>
      <sec id="article-24906.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Neck masses are commonly seen by primary caregivers, nurse practitioners, and internists. In most cases, the diagnosis of the neck mass is made by fine-needle aspiration. When medullary thyroid cancer (MTC) is diagnosed, the patient should be referred to a surgeon and an oncologist. In about 25% of cases, MTC is associated with the MEN syndrome.</p>
        <p>Surgical resection is the primary treatment modality for medullary thyroid cancer. Medullary thyroid cancer&#x000a0;does not respond to RAI or conventional chemotherapy. Thyroid-stimulating hormone (TSH)&#x000a0;suppression is not required for medullary thyroid cancer&#x000a0;as C cells do not have the&#x000a0;thyroid-stimulating hormone receptor. As mentioned previously all patients should be evaluated for hyperparathyroidism and pheochromocytoma. If pheochromocytoma is found, it should be removed before thyroid surgery.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30250937">[14]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30087948">[15]</ext-link></p>
        <p>Total thyroidectomy with central neck dissection is indicated for all patients with medullary thyroid cancer. Following surgery, patients need lifelong thyroxine and require monitoring for recurrence, which is rare. Most patients have a good prognosis after surgery in early-stage disease.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30548085">[16]</ext-link>&#x000a0;(Level V)</p>
      </sec>
      <sec id="article-24906.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24906&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24906">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/medullary-thyroid-cancer/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24906">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24906/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24906">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-24906.s16">
        <fig id="article-24906.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Medullary Thyroid Carcinoma. Classic cytological features seen in fine-needle aspiration (FNA) of MTC include a scattered arrangement of polygonal or triangular cells with azurophilic granules and eccentrically located nuclei displaying coarse, granular chromatin. Contributed by D Neelon, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Medullary__Carcinoma__Thyroid" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-24906.s17">
        <title>References</title>
        <ref id="article-24906.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boucai</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zafereo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cabanillas</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Thyroid Cancer: A Review.</article-title>
            <source>JAMA</source>
            <year>2024</year>
            <month>Feb</month>
            <day>06</day>
            <volume>331</volume>
            <issue>5</issue>
            <fpage>425</fpage>
            <page-range>425-435</page-range>
            <pub-id pub-id-type="pmid">38319329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caill&#x000e9;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Debreuve-Theresette</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vitellius</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Deguelte</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>La Manna</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zalzali</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Medullary Thyroid Cancer: Epidemiology and Characteristics According to Data From the Marne-Ardennes Register 1975-2018.</article-title>
            <source>J Endocr Soc</source>
            <year>2024</year>
            <month>Apr</month>
            <day>06</day>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>bvae084</fpage>
            <pub-id pub-id-type="pmid">38745826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gild</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Clifton-Bligh</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>Medullary Thyroid Cancer: Updates and Challenges.</article-title>
            <source>Endocr Rev</source>
            <year>2023</year>
            <month>Sep</month>
            <day>15</day>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>934</fpage>
            <page-range>934-946</page-range>
            <pub-id pub-id-type="pmid">37204852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haddad</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Bischoff</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bernet</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Blomain</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Busaidy</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Duh</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Ehya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goldner</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Haymart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Iagaru</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kandeel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lamonica</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Mandel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Markovina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McIver</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Raeburn</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Rezaee</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ridge</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Scheri</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Sipos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sippel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sturgeon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cassara</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Darlow</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>8</issue>
            <fpage>925</fpage>
            <page-range>925-951</page-range>
            <pub-id pub-id-type="pmid">35948029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wells</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Asa</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Dralle</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Elisei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Gagel</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Machens</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moley</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Pacini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Raue</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Frank-Raue</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schlumberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Waguespack</surname>
                <given-names>SG</given-names>
              </name>
              <collab>American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma</collab>
            </person-group>
            <article-title>Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.</article-title>
            <source>Thyroid</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>567</fpage>
            <page-range>567-610</page-range>
            <pub-id pub-id-type="pmid">25810047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cosway</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fussey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wykes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Sporadic medullary thyroid cancer: a systematic review and meta-analysis of clinico-pathological and mutational characteristics predicting recurrence.</article-title>
            <source>Thyroid Res</source>
            <year>2022</year>
            <month>Jul</month>
            <day>22</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <pub-id pub-id-type="pmid">35869537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vuong</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Odate</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ngo</surname>
                <given-names>HTT</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>TQ</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>TTK</given-names>
              </name>
              <name>
                <surname>Mochizuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakazawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Katoh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis.</article-title>
            <source>Endocr Relat Cancer</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>633</fpage>
            <page-range>633-641</page-range>
            <pub-id pub-id-type="pmid">29615431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jazdarehee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abdel-Rahman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Jacquier</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Remission of Ectopic Cushing Syndrome Secondary to Medullary Thyroid Cancer With Vandetanib and Selpercatinib.</article-title>
            <source>JCEM Case Rep</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>luad174</fpage>
            <pub-id pub-id-type="pmid">38283729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vitale</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tagliaferri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Caraglia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rampone</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ciccarelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bianco</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Abbruzzese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lupoli</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>85</volume>
            <issue>3</issue>
            <fpage>983</fpage>
            <page-range>983-8</page-range>
            <pub-id pub-id-type="pmid">10720027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raffaelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Voloudakis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barczynski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brauckhoff</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Durante</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gomez-Ramirez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koutelidakis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lorenz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Makay</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Materazzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pandev</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Randolph</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Tolley</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vriens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Musholt</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>European Society of Endocrine Surgeons (ESES) consensus statement on advanced thyroid cancer: definitions and management.</article-title>
            <source>Br J Surg</source>
            <year>2024</year>
            <month>Aug</month>
            <day>02</day>
            <volume>111</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">39158073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Asa</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Ezzat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sawka</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines.</article-title>
            <source>Curr Oncol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>338</fpage>
            <page-range>338-344</page-range>
            <pub-id pub-id-type="pmid">31708652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wells</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Gagel</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Dralle</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fagin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baudin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Elisei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jarzab</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vasselli</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Read</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Langmuir</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Schlumberger</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2012</year>
            <month>Jan</month>
            <day>10</day>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>134</fpage>
            <page-range>134-41</page-range>
            <pub-id pub-id-type="pmid">22025146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elisei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schlumberger</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;ffski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brose</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Licitra</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jarzab</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Medvedev</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kreissl</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Niederle</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hessel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yaron</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nelkin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>Cabozantinib in progressive medullary thyroid cancer.</article-title>
            <source>J Clin Oncol</source>
            <year>2013</year>
            <month>Oct</month>
            <day>10</day>
            <volume>31</volume>
            <issue>29</issue>
            <fpage>3639</fpage>
            <page-range>3639-46</page-range>
            <pub-id pub-id-type="pmid">24002501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hadoux</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Elisei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brose</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hoff</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jarzab</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Isaev</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kopeckova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wadsley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>F&#x000fc;hrer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Keam</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bardet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Tahara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Soldatenkova</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Capdevila</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>LJ</given-names>
              </name>
              <collab>LIBRETTO-531 Trial Investigators</collab>
            </person-group>
            <article-title>Phase 3 Trial of Selpercatinib in Advanced <italic>RET</italic>-Mutant Medullary Thyroid Cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>Nov</month>
            <day>16</day>
            <volume>389</volume>
            <issue>20</issue>
            <fpage>1851</fpage>
            <page-range>1851-1861</page-range>
            <pub-id pub-id-type="pmid">37870969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of selpercatinib in treating RET-altered MTC: A single-arm meta-analysis.</article-title>
            <source>Heliyon</source>
            <year>2024</year>
            <month>Jun</month>
            <day>15</day>
            <volume>10</volume>
            <issue>11</issue>
            <fpage>e31681</fpage>
            <pub-id pub-id-type="pmid">38841496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Subbiah</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mansfield</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Curigliano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brose</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>VW</given-names>
              </name>
              <name>
                <surname>Leboulleux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bowles</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Baik</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Adkins</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Keam</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Matos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Garralda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gainor</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Godbert</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sarker</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>9</volume>
            <issue>8</issue>
            <fpage>491</fpage>
            <page-range>491-501</page-range>
            <pub-id pub-id-type="pmid">34118198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marabelle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Ascierto</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Di Giacomo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>De Jesus-Acosta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Delord</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Geva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gottfried</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Penel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Piha-Paul</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Doi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Lopez-Martin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bang</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Frommer</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghori</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Joe</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Pruitt</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2020</year>
            <month>Jan</month>
            <day>01</day>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">31682550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kebebew</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Greenspan</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>OH</given-names>
              </name>
              <name>
                <surname>Woeber</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Grunwell</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Extent of disease and practice patterns for medullary thyroid cancer.</article-title>
            <source>J Am Coll Surg</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>200</volume>
            <issue>6</issue>
            <fpage>890</fpage>
            <page-range>890-6</page-range>
            <pub-id pub-id-type="pmid">15922202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24906.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rohmer</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vidal-Trecan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bourdelot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Niccoli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Murat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wemeau</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Borson-Chazot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schvartz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tabarin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chabre</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Chabrier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Caron</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rodien</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schlumberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baudin</surname>
                <given-names>E</given-names>
              </name>
              <collab>Groupe Fran&#x000e7;ais des Tumeurs Endocrines</collab>
            </person-group>
            <article-title>Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>96</volume>
            <issue>3</issue>
            <fpage>E509</fpage>
            <page-range>E509-18</page-range>
            <pub-id pub-id-type="pmid">21190982</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
